Research programme: DAR-NK cell based therapeutics - Karolinska Institutet/Sorrento Therapeutics
Latest Information Update: 21 Jun 2021
At a glance
- Originator Karolinska Institute; Sorrento Therapeutics
- Class Antineoplastics; Fab fragments; Gene therapies; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer
Most Recent Events
- 11 Jun 2021 Early research in Cancer in Sweden (Parenteral)
- 11 Jun 2021 Early research in Cancer in USA (Parenteral)
- 04 Jun 2021 Sorrento Therapeutics enters into an collaborative agreement with Karolinska Institutet to develop novel cell-based therapeutics using natural killer (NK) cells derived from induced pluripotent stem cells (iPSCs)